Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 8/20 | 0.44 |
| ▸ | CTSS | P25774 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369240 | 1.00 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL1563568 | 1.00 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL20131845 | 0.92 | KMT2A (0.47) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL29068653 | 0.83 | CA1 (0.49) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL15947338 | 0.83 | CA1 (0.49) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL23849248 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL148099 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL256594 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL23607312 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A | |
| SCHEMBL148100 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | NOVOSTAR PHARMACEUTICALS, LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4338737-A1 | PARP7 INHIBITOR AND USE THEREOF | Novostar Pharmaceuticals, Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-09-21 | — | — | US | disclosed |
| WO-2023137113-A2 | CHEMICALLY REVERSIBLE 2´-OH ACYLATION PROTECTS RNA FROM HYDROLYTIC AND ENZYMATIC DEGRADATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-20 | — | — | WO | disclosed |
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | CELGENE CAR LLC (BM) | 2023-05-23 | — | — | US | disclosed |
| US-11639334-B2 | Methods for synthesis of oxypicolinamides | CORTEVA AGRISCIENCE LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11623927-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-04-11 | — | — | US | disclosed |
| US-11623927-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-04-11 | — | — | US | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1294747-B1 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR SA (ES) | 2008-04-30 | — | — | EP | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
| US-20080009026-A1 | FLUOROGENIC PROTEIN KINASE SUBSTRATES | INVITROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070276017-A1 | Thiadiazoline Derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-11-29 | — | — | US | disclosed |
| CN-1443173-A | Substituted imidazoles as TAFI a inhibitors | PFIZER LTD (US) | 2003-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623927-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules | TUBB1, TUBA1B, TUBA1C | CA1 3852/4885CA2 4304/4885CA7 4057/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | CA1 3165/4885CA2 3259/4885CA7 3861/4885 |
| US-20070276017-A1 | Thiadiazoline Derivative | BRD7, NR3C2, NR5A2 | CA1 4657/4885CA2 3840/4885CA7 1454/4885 |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, TYMP, RNGTT | CA1 3827/4885CA2 4265/4885CA7 3720/4885 |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | PARP1, PARP3, PARP11 | CA1 3814/4885CA2 3940/4885CA7 414/4885 |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | CA1 993/4885CA2 4013/4885CA7 850/4885 |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | CA1 4685/4885CA2 3104/4885CA7 2245/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | CA1 4844/4885CA2 4487/4885CA7 4692/4885 |
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | WEE2, WEE1, CDK2 | CA1 3429/4885CA2 2645/4885CA7 3885/4885 |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | PDE4B, PDE4A, PDE3B | CA1 2955/4885CA2 491/4885CA7 356/4885 |
| US-11639334-B2 | Methods for synthesis of oxypicolinamides | CYP51A1, CYP4X1, CYP4F3 | CA1 1613/4885CA2 445/4885CA7 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.